Crinetics Pharmaceuticals, Inc.
CRNX
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as weā¦ read more
Healthcare
Biotechnology
7 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$36.72
Price-4.15%
-$1.59
1Y
Price
Market Cap
$3.872b
Mid
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-1297.0%
EBITDA Margin-1191.0%
Net Profit Margin-1169.4%
Free Cash Flow Margin-1297.0%
EBITDA Margin-1191.0%
Net Profit Margin-1169.4%
Free Cash Flow MarginRevenue
$18.069m
+134.8%
1y CAGR+233.8%
3y CAGR+171.5%
5y CAGREarnings
-$496.388m
-6.7%
1y CAGR-33.9%
3y CAGR-33.1%
5y CAGREPS
-$5.14
-3.8%
1y CAGR-12.7%
3y CAGR-13.8%
5y CAGRBook Value
$1.281b
$1.401b
Assets$120.677m
Liabilities$47.855m
DebtDebt to Assets
3.4%
-0.1x
Debt to EBITDAFree Cash Flow
-$419.516m
-9.3%
1y CAGR-36.9%
3y CAGR-39.2%
5y CAGRNo items found.
Press Releases
Statements and updates from the company